We aim to develop novel LBP (Live Biotherapeutics Products) to cure intractable disorders like autoimmunity, cancer, and autism spectrum disorders. With continued advancement in cutting-edge research based on our solid scientific infrastructures (germ-free mouse facility), qualified scientists (Immunologist and AI specialist), and merits of academic research environment (POSTECH campus), we aim to become a world-leading microbiome therapeutics company. We are sure that our novel therapeutics could cure patients suffering from various immune disorders.
Our company has developed an innovative platform technology, named “Avatiome,” to identify the best drug candidates, confirm Immuno-modulatory properties in germ-free mice systems, define effective molecules, and elucidate mechanisms of action of related products. Furthermore, by employing humanized mouse model containing human immune cell components and microbiota, we evaluate the translational possibilities of utilizing preclinical data for clinical applicability.
One of our strong research capabilities is to define the effector molecules that recapitulate the functionalities of LBP and elucidate their mechanisms of action, which enable us to design an optimal combination of drug candidates with our LBP candidates. Accordingly, we have been attracting global attention by publishing many articles in prestigious academic journals, including Science Immunology, Immunity, and Nature Communications.
ImmunoBiome will leap forward as an innovative new drug development company to cure intractable diseases like cancer and autoimmune diseases based on our solid scientific research.
1996 - 2001
Ph.D. in Immunology at Weizmann Institute of Science (Israel)
1987 - 1989
Master Sc. in Biochemistry at Korea University
1983 - 1987
Bachelor Sc. in Life Sciences at Korea University
2014 - Present
Professor, Department of Life Sciences, POSTECH (Korea)
2012 - 2013
Professor, Department of Life Sciences, GIST (Korea)
2001 - 2003
Postdoc. Department of Pathology, Harvard Medical School (USA)
1991 - 1996
Senior Researcher, R&D Center, Chong Kun Dang Pharmaceutical Company
2015 - Current
Chairman, Int’l Probiotics and Prebiotics Conference
2018 - 2021
Board of directors, Pharmabiotics Research Institute (France)
Scientific advisory board, DuPont Nutrition & Health (2017, 2019) etc
2015 - Present
Beneficial Microbes (ISSN: 1876-2891)
2018 - 2020
Review editor, Frontiers in Immunology
2021 - Present
Associate Editor, Frontiers in Immunology
2019 - Present
Vaccines, (ISSN 2076-393X)